Analysts See $-0.18 EPS for Vascular Biogenics Ltd. (VBLT)

July 14, 2018 - By Sonya McDaniel

Vascular Biogenics Ltd. (NASDAQ:VBLT) Logo

Analysts expect Vascular Biogenics Ltd. (NASDAQ:VBLT) to report $-0.18 EPS on August, 13.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.18 EPS. After having $-0.24 EPS previously, Vascular Biogenics Ltd.’s analysts see -25.00 % EPS growth. The stock increased 3.53% or $0.08 during the last trading session, reaching $2.2. About 115,491 shares traded. Vascular Biogenics Ltd. (NASDAQ:VBLT) has declined 60.91% since July 14, 2017 and is downtrending. It has underperformed by 73.48% the S&P500.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Coverage

Among 4 analysts covering Vascular Biogenics (NASDAQ:VBLT), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Vascular Biogenics had 6 analyst reports since March 8, 2018 according to SRatingsIntel. Chardan Capital Markets downgraded Vascular Biogenics Ltd. (NASDAQ:VBLT) on Friday, March 9 to “Neutral” rating. The rating was downgraded by H.C. Wainwright on Thursday, March 8 to “Neutral”. The firm has “Hold” rating given on Thursday, March 8 by Piper Jaffray. The rating was maintained by H.C. Wainwright with “Hold” on Thursday, March 22. The rating was maintained by H.C. Wainwright on Friday, May 18 with “Hold”. The rating was downgraded by JMP Securities to “Hold” on Thursday, March 8.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company has market cap of $78.88 million. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. It currently has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

More notable recent Vascular Biogenics Ltd. (NASDAQ:VBLT) news were published by: Benzinga.com which released: “54 Biggest Movers From Yesterday” on June 27, 2018, also Nasdaq.com with their article: “VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market” published on June 26, 2018, Benzinga.com published: “40 Stocks Moving In Tuesday’s Mid-Day Session” on June 26, 2018. More interesting news about Vascular Biogenics Ltd. (NASDAQ:VBLT) were released by: Nasdaq.com and their article: “Publication by VBL Therapeutics Highlights MOSPD2 as a Potential New Target for Breast Cancer Therapy” published on July 10, 2018 as well as Globenewswire.com‘s news article titled: “VBL Therapeutics Announces Closing of $15.5 Million Registered Direct Offering” with publication date: June 27, 2018.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.